Novartis has published results from a clinical trial of Pear Therapeutics' new digital therapeutic for schizophrenia, and the results don't paint a rosy picture.
The single-blinded 112-person trial found no difference between the Pear app and a placebo app in any outcome measure, including the primary outcome measure of reducing schizophrenia symptoms. However, the trial did further establish the...
The life science world has continued to deepen its interest in the digital space. While the mainstream life science news of the year was research on the coronavirus vaccine, when it came to digital the industries efforts were more varied. We saw new partnerships between pharma and digital health around topics such as respiration health, cardiovascular conditions and real-world data.
This year we...
Over the last few weeks three pharma companies released promising trial data from their COVID-19 vaccines, bringing a possible light at the end of the tunnel to the pandemic. While the vaccines are still yet to hit the market, discussion of distribution is beginning to surface. Blockchain, a technology that makes the data easy to verify and difficult to falsify, has come into the conversation. ...
The femtech world is beginning to venture out of the boundaries of reproductive health and into other areas of women’s health, according to panelists at Bayer G4A summit yesterday.
Over the summer, Rock Health report that about 65% of all femtech funding has gone into fertility, pregnancy or motherhood. Today innovators are looking beyond the reproductive umbrella, at how technology and research...
Pharma giant Bayer is kicking off new digital collaboration efforts in the fields of cardiometabolic and renal disease, oncology and women’s health via a new initiative, dubbed the G4A Digital Health Partnership Program.
The program is split into two tracks, one for early-stage companies and another for more experienced companies. It tapped Caria, an AI and data company that matches people...
Finnish digital health startup Popit and Almirall, a global biopharmaceutical company focused on skin health are collaborating on a support tool for patients with psoriasis.
The solution consists of Popit’s consumer smart device that automatically tracks when medication is taken and reminds patients if a dose has been missed via an accompanying app. It uses a unique piece of hardware which the...
Novartis's digital strategy hasn't changed too much since MobiHealthNews spoke with the pharma company in 2018. But, at the HLTH virtual conference this week, Novartis Chief Digital Officer Betrand Bodson reiterated the company's four-part strategy, focusing especially on its partnerships, including those with Microsoft, Amazon and China's Tencent.
"We started this agenda in earnest two and a...
Abbott announced that its Libre Sense Glucose Sport Biosensor has achieved a CE Mark, paving the way for a European roll-out.
The Libre Sense biosensor provides continuous glucose monitoring (CGM) to help athletes understand the efficacy of their nutrition choices on training and competition.
Based on Abbott's FreeStyle Libre technology for people living with diabetes, it is the first personal-...
It’s no secret that digital is shaping what clinical trials will look like in the future. A recently published position paper published in Nature discusses the potentials and challenges of digital clinical trials. The paper builds on a workshop held by the U.S. National Institutes of Health and the National Science Foundation in April of 2019.
One of the big opportunities that the paper outlines...
The United States Postal Service has been at the heart of a bitter partisan divide over the last few months of COVID-19 and the U.S. election season.
Prominent Democratic politicians have alleged that recent reforms and administrative changes ushered by recently appointed Postmaster General Louis DeJoy have led to widespread service delays across the country. At the same time, President Donald...
